


Fig. 1 Schematic view of equipment; not to scale






Side views of test stage; not to scale










Top view of test stage; not to scale


sectional representations of portions of the test-array/detector layers: not to scale

ANDE 8 O HUL











b)



c)





Carbamylcholine Response (1 mM, five spots)




Figure 6



Carbamylcholine Response (1 mM, five spots)




Figure 7



FCCP Response (50 µM, 5 x 5 grid of spots)




Figure 8



FCCP Response (50 µM, five central spots)




Figure 9



FCCP Dose-response (50, 5, 0.5, 0.05 and 0.005 μ M, 5 x 5 grid)




Figure 10



FCCP Dose-response (50, 5, 0.5, 0.05 and 0.005 μM)




Figure 11



Ionomycin and Thapsigargin responses




Figure 12



Ionomycin and Thapsigargin responses (mean of two to three responses)




Figure 13